YNIOS Pharma
The micro format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.
Balance sheet
balance sheet total €794,459 on 31-12-2025in euro
in euro
Position in the sector
59.6%
Higher than 72% of the 166 companies filing micro accounts in chemicals (NACE 20) in 2025.
0.04
Lower than 95% of the 154 companies filing micro accounts in chemicals (NACE 20) in 2025.
-28.8%
Higher than 16% of the 158 companies filing micro accounts in chemicals (NACE 20) in 2025.
Net result: bottom quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: bottom quarter
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 202210 months |
|---|---|---|---|---|---|
| -105,209 | 392,499 | -162,217 | -133,939 | ||
| -112,210 | 391,532 | -162,991 | -133,977 | ||
| 193,754 | 585,521 | 97,718 | 104,534 | ||
| -252,439 | 206,958 | 44,314 | - | ||
| -307,374 | -1,410 | 7,780 | -31,511 | ||
| 59.6% | 72.4% | 34.5% | 56.6% | ||
| 0.04 | 0.99 | 1.18 | 0.43 | ||
| 0.68 | 0.38 | 1.89 | 0.77 | ||
| -48.3% | 48.7% | -260.1% | -187.5% | ||
| -28.8% | 35.3% | -89.8% | -106.2% | ||
| -10.30 | over 100 | -209.63 | -2213.86 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 202210 months |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
794,459 | 970,290 | 218,657 | 127,086 | |
21/28 |
780,937 | 703,876 | 167,762 | 103,502 | |
21 |
780,937 | 703,876 | 167,762 | 103,502 | |
29/58 |
13,522 | 266,415 | 50,895 | 23,584 | |
40/41 |
8,169 | 8,623 | 661 | 17,665 | |
40 |
- | - | - | 9,600 | |
41 |
8,169 | 8,623 | 661 | 8,065 | |
54/58 |
4,753 | 257,192 | 50,234 | 5,919 | |
490/1 |
600 | 600 | - | - | |
| Balance sheet: equity and liabilities | |||||
10/49 |
794,459 | 970,290 | 218,657 | 127,086 | |
10/15 |
473,563 | 702,466 | 75,542 | 71,991 | |
10/11 |
691,800 | 691,800 | 407,000 | 207,000 | |
11 |
- | - | - | 207,000 | |
1100/10 |
- | - | - | 207,000 | |
14 |
-218,237 | 10,666 | -331,458 | -135,009 | |
17/49 |
320,896 | 267,824 | 143,115 | 55,095 | |
17 |
- | - | 100,000 | - | |
170/4 |
- | - | 100,000 | - | |
42/48 |
320,896 | 267,824 | 43,115 | 55,095 | |
44 |
2,500 | 7,459 | 22,798 | 54,771 | |
440/4 |
2,500 | 7,459 | 22,798 | 54,771 | |
45 |
378 | 308 | 4,372 | 324 | |
450/3 |
378 | 308 | 4,372 | 324 | |
47/48 |
318,019 | 260,057 | 15,946 | - | |
| Income statement | |||||
76A |
- | 40,812 | - | - | |
9900 |
-4,809 | 392,886 | -161,833 | -133,591 | |
630 |
116,693 | 49,408 | 33,458 | 1,032 | |
640/8 |
400 | 387 | 384 | 348 | |
66A |
100,000 | - | - | - | |
9901 |
-221,902 | 343,091 | -195,675 | -134,971 | |
75/76B |
- | 236 | - | 22 | |
75 |
- | 236 | - | 22 | |
65/66B |
10,217 | 1,203 | 774 | 61 | |
65 |
10,217 | 1,203 | 774 | 61 | |
9903 |
-232,118 | 342,124 | -196,449 | -135,009 | |
67/77 |
-3,215 | - | - | - | |
9904 |
-228,903 | 342,124 | -196,449 | -135,009 | |
9905 |
-228,903 | 342,124 | -196,449 | -135,009 | |
| Appropriation of the result | |||||
9906 |
-218,237 | 10,666 | -331,458 | -135,009 | |
14P |
10,666 | -331,458 | -135,009 | - | |
| Document | |||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 12-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankInvestments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Intangible fixed assets | €193,754 | €585,521 | €97,718 | €104,534 |
| €116,693 | €49,408 | €33,458 | €1,032 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Insights on YNIOS Pharma
The operating result for 2025 is a loss of €221,902, after a profit of €343,091 in 2024. It is the lowest result since 2023.
Debt's share of the balance-sheet total rises from 27.6% to 40.4%. Equity is lower and debt is higher.